AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-21. Canceled

22.   (Currently amended)   An albumin fusion protein comprising two or more tandemly oriented GLP-1 polypeptides, wherein said GLP-1 polypeptides are selected from wild-type GLP-1, GLP-1 fragments, ~~or~~ and GLP-1 variants, ~~wherein said GLP-1 fragments or GLP-1 variants have GLP-1 activity~~ fused to albumin comprising the amino acid sequence of SEQ ID NO:1038, an albumin fragment, or albumin variant thereof, wherein said albumin fragment or albumin variant increases the serum plasma half-life of the unfused GLP-1 polypeptides, and wherein said fusion protein has GLP-1 activity.

23.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from wild type GLP-1 sequences.

24.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 fragment sequences.

25.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 variant sequences.

26.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one wild type GLP-1 sequence fused to at least one GLP-1 fragment sequence.

27.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one wild type GLP-1 sequence fused to at least one GLP-1 variant sequence.

28.   (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP-1 polypeptides are selected from at least one GLP-1 fragment sequence fused to at least one GLP-1 variant sequence.

29.   (Previously presented)   The albumin fusion protein of claim 22, wherein said GLP-1 fragments or GLP-1 variants are selected from:

a.   GLP-1(9-36);

b.   GLP-1(7-36);

c.   GLP-1(7-36(A8G)); and

d.   GLP-1(7-36(A8S)).

30.   (Previously presented)   The albumin fusion protein of claim 29, wherein said GLP-1 fragments or GLP-1 variants are selected from two tandemly oriented GLP-1(7-36(A8G)).

31.   (Previously presented)   The albumin fusion protein of claim 30, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the N-terminus to albumin.

32.   (Previously presented)   The albumin fusion protein of claim 30, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the C-terminus to albumin.

33. (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP -1 polypeptides are fused at the N-terminus to albumin.

34. (Previously presented)   The albumin fusion protein of claim 22, wherein said tandemly oriented GLP -1 polypeptides are fused at the C-terminus to albumin.

35. (Previously presented)   The albumin fusion protein of claim 22, produced from a host cell comprising a construct which expresses said albumin fusion protein, wherein said construct is selected from:

a.   2900;

b.   2964;

c.   2803;

d.   2804;

e.   2945;

f.   2982;

g.   3070;

h.   3027;

i.   3028;

j.   3045;

k.   3046;

l.   3069;

m.   3071;

n.   3072;

o.   3085;

p.   3086;

q.   3087;

r.   3309; and

s.   2904.

36.   (Previously presented)   The albumin fusion protein of claim 22, which is non-glycosylated.

37.   (Previously presented)   The albumin fusion protein of claim 22, which is expressed in yeast.

38.   (Previously presented)   The albumin fusion protein of claim 37, wherein said yeast is a S. cerevisiae.

39.   (Previously presented)   The albumin fusion protein of claim 37, wherein said yeast is glycosylation deficient.

40.   (Previously presented)   The albumin fusion protein of claim 37, wherein said yeast is glycosylation and protease deficient.

41.   (Previously presented)   The albumin fusion protein of claim 22, which is expressed by a mammalian cell.

42.   (Previously presented)   The albumin fusion protein of claim 41, wherein said mammalian cell is a CHO cell.

43.   (Previously presented)   The albumin fusion protein of claim 22, wherein the albumin fusion protein further comprises a secretion leader sequence.

44.   (Previously presented)   A composition comprising the albumin fusion protein of claim 22 and a pharmaceutically acceptable carrier.

45.   (Currently amended)   A method of treating a patient with diabetes, comprising administering an effective amount of the albumin fusion protein of any one of claims 22-43 or the composition of claim 44.